angiotech pharmaceuticals completes sale to investor syndicate led by vivo capital and zq capital angiotech pharmaceuticals completes sale to investor syndicate led by vivo capital and zq capital news provided by vivo capital mar    et share this article palo alto calif and vancouver british columbia march   prnewswire  angiotech pharmaceuticals a leading medical device company focused on high value medical consumables in the wound closure and ophthalmology sectors today announced the completion of its sale to a group of investors led by vivo capital llc and zq capital limited  the investment syndicate also includes gso capital partners lp china orient asset management international holding limited fung shing investments ltd zz capital co ltd abci investment management limited cathay venture inc and nan fung group  in addition business development companies managed by affiliates of fs investments and subadvised by an affiliate of gso capital partners lp gso a division of the blackstone group abci investment management limited and china minsheng banking corporation limited hong kong branch provided senior secured financing for the transaction  the terms of the transaction were not disclosed  angiotech is a leading diversified medical device manufacturer of branded private label and oem products  the company has more than  employees worldwide has manufacturing facilities in england puerto rico mexico and germany and sells to customers in over  countries  omelveny  myers llp was legal advisor to the investment syndicate and paul hastings llp and magstone law were legal advisors to zq capital piper jaffray  co was financial advisor and irell  manella llp served as legal advisor respectively to angiotech about vivo capital vivo capital is a global healthcare focused investment firm formed in  with over  billion under management  vivo capital has offices in palo alto california beijing shanghai and taipei  vivos current portfolio includes more than  private and public biotechnology companies in the areas of biopharmaceuticals specialty pharmaceuticals and medical devices more information can be found at wwwvivocapitalcom about zq capital limited zq capital is an investment firm headquartered in hong kong  the firm specializes in identifying investing in and partnering with global companies to realize their growth potential in the chinese market by levering zq capitals deep local knowledge of china as well as extensive relationships with financial institutions and leading entrepreneurs throughout asia about china orient asset management international holding limited china orient asset management international holding limited coami is headquartered in hong kong and is a whollyowned subsidiary and primary overseas platform of china orient asset management co ltd  as of  december  coami has assets over hkd bn the key businesses of coami include investment corporate finance advisory nonperforming asset acquisitions and asset management about fung shing investment limited fung shing investment limited is an investment company with extensive experience and knowledge fung shing invests in various sectors including but not limited to media telecom healthcare real estates and financial institutions about zz capital co ltd zz capital co ltd zz capital is a global investment firm headquartered in beijing and an affiliate of zhongzhi group a leading financial services company with more than usbn aum across a variety of investment and wealth management platforms zz capital and its affiliate zz capital international a hong kong listed company are the global flagship private equity investment vehicles for the zhongzhi group zz capital seeks buyout and investment opportunities in the healthcare financial services tmt education media and advanced manufacturing sectors to create true partnerships drive value enhancement and leverage its unique positioning in china the business operates offices in beijing hong kong new york san francisco london and tel aviv about cathay venture inc cathay venture is an evergreen fund whollyowned by cathay financial holding based in taipei taiwan cathay financial group establishes its presence in taiwan on december   with registered capital of ntd billion composed of insurance securities banking and other diversified financial institutions cathay financial holdings is a fullfunctioning financial platform about nan fung group founded in  nan fung group is a fully integrated multidisciplinary conglomerate based in hong kong with global interests in real estate development and investment financial investment hotels and shipping about china minsheng banking corporation limited hong kong branch opened on  march  china minsheng banking corporation limited hong kong branch cmbc hk is the first and only overseas branch of china minsheng banking corp ltd  cmbc hk has been active in providing offshore transaction based financing to its pe or corporate clients about angiotech angiotech pharmaceuticals  has developed and manufactured branded private label and oem surgical instruments for over  years the company offers one of the most comprehensive portfolios of blades and sutures available including innovative products such as the quill knotless tissueclosure device headquartered in vancouver ca angiotech devotes itself to exceeding the needs of the specialty surgery market having trusted partnerships within dental ophthalmic plastic surgery dermatology orthopedics urology microsurgery veterinary and trauma specialties the key shareholders in angiotech include affiliates of blue mountain capital llc courage capital management llc and cetus capital llc to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesangiotechpharmaceuticalscompletessaletoinvestorsyndicateledbyvivocapitalandzqcapitalhtml source vivo capital related links httpvivocapitalcom dec    et preview vivo capital and zq capital limited enter into an agreement to acquire angiotech pharmaceuticals my news release contains wide tables view fullscreen you just read angiotech pharmaceuticals completes sale to investor syndicate led by vivo capital and zq capital news provided by vivo capital mar    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search vivo capital llc private company information  bloomberg july    am et capital markets company overview of vivo capital llc snapshot people company overview vivo capital llc is a private equity and venture capital firm specializing in incubation seed startup mezzanine and pipe investments in private and public companies the firm seeks to invest in all financing stages from series a to public companies it primarily invests in healthcare biotechnology and life science companies the firm also seeks to invest in companies with laterstage therapeutic products in clinical development it typically makes investments in united states and asia pacific based companies with a focus on later development stage pharmaceutical and medical device companies in the us and in revenue stage healthcare companies in greater china vivo capital llc was f vivo capital llc is a private equity and venture capital firm specializing in incubation seed startup mezzanine and pipe investments in private and public companies the firm seeks to invest in all financing stages from series a to public companies it primarily invests in healthcare biotechnology and life science companies the firm also seeks to invest in companies with laterstage therapeutic products in clinical development it typically makes investments in united states and asia pacific based companies with a focus on later development stage pharmaceutical and medical device companies in the us and in revenue stage healthcare companies in greater china vivo capital llc was founded in  and is based in palo alto california with additional offices in beijing china shanghai china and taipei taiwan detailed description  hamilton avenuesuite palo alto ca united statesfounded in  phone  fax  vivocapitalcom key executives for vivo capital llc dr frank f c kung phd senior managing partner age  mr hwachie lee managing director and chief investment officer dr edgar g engleman md managing partner and founding member age  dr albert cha md phd managing partner age  dr chenming yu md mba managing partner age  compensation as of fiscal year  vivo capital llc key developments vivo capital llc presents at th annual private equity  venture forum jul jun   vivo capital llc presents at th annual private equity  venture forum jul  venue new york new york united states speakers frank f c kung senior managing partner vivo capital llc presents at annual china healthcare investment conference mar through mar mar   vivo capital llc presents at annual china healthcare investment conference mar through mar venue shangrila pudong hotel shanghai china presentation date  speakers mar edgar g engleman managing partner and founding member mar chenming yu managing partner cyber cao managing director frank f c kung senior managing partner michael chang managing director vivo capital llc presents at th annual conference biotech showcase jan nov   vivo capital llc presents at th annual conference biotech showcase jan  venue hilton san francisco union square  ofarrell street san francisco ca  united states similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target private placement july   menlo therapeutics inc private placement june   zai lab limited private placement june   selecta biosciences inc request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact vivo capital llc please visit vivocapitalcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close vivo capital  healthcare focused investment firm lp access    select page vivo capital is a healthcare focused investment firm formed in  with over  billion under management vivo capital is currently making investments from its m eighth fund into promising private and public healthcare companies in the us and greater china and from its m panda fund into promising earlystage innovative healthcare companies vivo employs a unique multipronged strategy of identifying and working with companies with promising therapeutic products at all stages in the us and revenue stage companies in china vivo capital has offices in palo alto california beijing shanghai and taipei with over  years of scientific expertise and operating experience in healthcare vivo makes investment decisions for the funds and helps its portfolio companies develop corporate strategy facilitate strategic alliances including crossborder partnerships recruit management and acquire new products and technologies to accelerate growth vivo’s current portfolio includes more than  private and public biotechnology companies in the areas of biopharmaceuticals specialty pharmaceuticals and medical devices zai lab secures series c financing june  wuxi biologics prices hk ipo at top as investors seek growth business june  biohaven announces pricing of initial public offering of common shares may  verona pharma prices ipo at  april   vivo capital  healthcare focused investment firm lp access    select page vivo capital is a healthcare focused investment firm formed in  with over  billion under management vivo capital is currently making investments from its m eighth fund into promising private and public healthcare companies in the us and greater china and from its m panda fund into promising earlystage innovative healthcare companies vivo employs a unique multipronged strategy of identifying and working with companies with promising therapeutic products at all stages in the us and revenue stage companies in china vivo capital has offices in palo alto california beijing shanghai and taipei with over  years of scientific expertise and operating experience in healthcare vivo makes investment decisions for the funds and helps its portfolio companies develop corporate strategy facilitate strategic alliances including crossborder partnerships recruit management and acquire new products and technologies to accelerate growth vivo’s current portfolio includes more than  private and public biotechnology companies in the areas of biopharmaceuticals specialty pharmaceuticals and medical devices zai lab secures series c financing june  wuxi biologics prices hk ipo at top as investors seek growth business june  biohaven announces pricing of initial public offering of common shares may  verona pharma prices ipo at  april   portfolio  vivo capital lp access    select page portfolio united states active aclaris therapeutics advanced accelerator applications agile therapeutics airxpanders akari therapeutics ascendis pharma biohaven pharma aurinia biopharmx crispr therapeutics eiger foamix impel neuropharma kala pharmaceuticals kalvista pharmaceuticals minerva surgical nabriva therapeutics outpost medicine regenxbio revance therapeutics selecta biosciences semnur pharmaceuticals sentreheart sierra oncology soleno therapeutics strongbridge biopharma surgical specialties synapse biomedical trevena tria beauty verona pharma zai lab exited china early stage panda aclaris therapeutics nasdaq acrs is a specialty pharmaceutical company focused on the development of novel dermatological therapies advanced accelerator applications nasdaq aaap is pioneering the field of molecular nuclear medicine and aims to provide predictive preventive and personalized tools and procedures that will radically transform healthcare management both for healthcare professionals and patients agile therapeutics nasdaq agrx is a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products airxpanders asx axp is a medical device company that has developed the aeroform tissue expander aeroform is a patient controlled breast tissue expander for reconstructive surgeries such as breast reconstruction after mastectomy akari therapeutics nasdaq aktx is developing anticomplement and antiinflammatory molecules as lifetransforming treatments for a wide range of severe and orphan autoimmune and inflammatory diseases ascendis pharma nasdaq asnd develops differentiated prodrug versions of highvalue drugs the company’s proprietary transcon technology is used to generate product candidates that are improved versions of existing drugs yielding more effective lowerrisk therapeutics with new patent lives aurinia pharmaceuticals is developing and delivering innovative products to patients suffering from debilitating diseases such as lupus nephritis ln biohaven pharma nasdaq bhvn is a publicly held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting orphan neurologic indications and other neurological pathways biopharmx nyse bpmx provides innovative healthcare products through its unique patented platform technologies for pharmaceutical overthecounter otc and supplement applications crispr therapeutics is a world leader in crispr cas gene editing technology eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis our pipeline includes preclinical nces from discovery as well as repurposed clinical agents to treat hepatitis c and hepatitis d foamix nasdaq fomx is a specialty pharmaceutical company focused on the development and commercialization of proprietary innovative and differentiated topical drugs for dermatological therapy impel neuropharma is using its precision olfactory delivery pod nasal devices to develop therapies for diseases of the brain such as migraine and alzheimer’s kala is a company developing novel therapies to treat serious eye conditions kalvista pharmaceuticals nasdaq kalv is creating a new generation of small molecule protease inhibitors minerva surgical is developing nextgeneration technology for treating excessive menstrual bleeding nabriva nasdaq nbrv is an antiinfective company developing a novel therapy for community acquired pneumonia outpost medicine is developing a novel therapy for overactive bladder and irritable bowel syndrome regenxbio nasdaq rgnx is a gene therapy platform company that is leveraging its proprietary nav® technology to advance the development of lifechanging adenoassociated viral aav treatments for lysosomal storage disorders ocular diseases and other unmet clinical needs revance therapeutics nasdaq rvnc is a specialty pharmaceutical company focused on discovering and developing therapeutic products in the areas of aesthetic medicine and therapeutic dermatology selecta is a clinicalstage biopharmaceutical company advancing a pipeline of differentiated products designed to modulate the immune system semnur pharmaceuticals is a pharmaceutical company developing an injectable product for the treatment of lower back pain sentreheart is a commercial stage medical device company with a novel suture delivery and tissue closure device for multiple clinical applications sierra oncology nasdaq srra is a clinical stage drug development company advancing next generation dna damage response ddr therapeutics for the treatment of patients with cancer soleno therapeutics nasdaq slno is developing a novel treatment for patients with praderwilli syndrome pws strongbridge biopharma focuses on rare diseases has resulted in a portfolio of innovative treatments for rare endocrine conditions surgical specialties is a medical device company that is marketing surgical products on a worldwide basis synapse biomedical is a medical device company developing neurostimulation products the company’s products have been approved by the fda for patients with spinal cord injury and amyotrophic lateral sclerosis trevena inc nasdaq trvn is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of gpcr targeted medicines tria beauty is a leader in lightbased therapeutic beauty systems that incorporate clinicallyproven aesthetic technologies for athome personal care regimens verona pharma lse aimvrpl is focused on developing new drugs for a range of respiratory diseases zai lab is a shanghaibased biopharmaceutical company our globallyexperienced drug development team is passionate about bringing transformative medicines to china and discovering and developing our own therapeutics for patients worldwide portfolio  vivo capital lp access    select page portfolio united states active aclaris therapeutics advanced accelerator applications agile therapeutics airxpanders akari therapeutics ascendis pharma biohaven pharma aurinia biopharmx crispr therapeutics eiger foamix impel neuropharma kala pharmaceuticals kalvista pharmaceuticals minerva surgical nabriva therapeutics outpost medicine regenxbio revance therapeutics selecta biosciences semnur pharmaceuticals sentreheart sierra oncology soleno therapeutics strongbridge biopharma surgical specialties synapse biomedical trevena tria beauty verona pharma zai lab exited china early stage panda aclaris therapeutics nasdaq acrs is a specialty pharmaceutical company focused on the development of novel dermatological therapies advanced accelerator applications nasdaq aaap is pioneering the field of molecular nuclear medicine and aims to provide predictive preventive and personalized tools and procedures that will radically transform healthcare management both for healthcare professionals and patients agile therapeutics nasdaq agrx is a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products airxpanders asx axp is a medical device company that has developed the aeroform tissue expander aeroform is a patient controlled breast tissue expander for reconstructive surgeries such as breast reconstruction after mastectomy akari therapeutics nasdaq aktx is developing anticomplement and antiinflammatory molecules as lifetransforming treatments for a wide range of severe and orphan autoimmune and inflammatory diseases ascendis pharma nasdaq asnd develops differentiated prodrug versions of highvalue drugs the company’s proprietary transcon technology is used to generate product candidates that are improved versions of existing drugs yielding more effective lowerrisk therapeutics with new patent lives aurinia pharmaceuticals is developing and delivering innovative products to patients suffering from debilitating diseases such as lupus nephritis ln biohaven pharma nasdaq bhvn is a publicly held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting orphan neurologic indications and other neurological pathways biopharmx nyse bpmx provides innovative healthcare products through its unique patented platform technologies for pharmaceutical overthecounter otc and supplement applications crispr therapeutics is a world leader in crispr cas gene editing technology eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis our pipeline includes preclinical nces from discovery as well as repurposed clinical agents to treat hepatitis c and hepatitis d foamix nasdaq fomx is a specialty pharmaceutical company focused on the development and commercialization of proprietary innovative and differentiated topical drugs for dermatological therapy impel neuropharma is using its precision olfactory delivery pod nasal devices to develop therapies for diseases of the brain such as migraine and alzheimer’s kala is a company developing novel therapies to treat serious eye conditions kalvista pharmaceuticals nasdaq kalv is creating a new generation of small molecule protease inhibitors minerva surgical is developing nextgeneration technology for treating excessive menstrual bleeding nabriva nasdaq nbrv is an antiinfective company developing a novel therapy for community acquired pneumonia outpost medicine is developing a novel therapy for overactive bladder and irritable bowel syndrome regenxbio nasdaq rgnx is a gene therapy platform company that is leveraging its proprietary nav® technology to advance the development of lifechanging adenoassociated viral aav treatments for lysosomal storage disorders ocular diseases and other unmet clinical needs revance therapeutics nasdaq rvnc is a specialty pharmaceutical company focused on discovering and developing therapeutic products in the areas of aesthetic medicine and therapeutic dermatology selecta is a clinicalstage biopharmaceutical company advancing a pipeline of differentiated products designed to modulate the immune system semnur pharmaceuticals is a pharmaceutical company developing an injectable product for the treatment of lower back pain sentreheart is a commercial stage medical device company with a novel suture delivery and tissue closure device for multiple clinical applications sierra oncology nasdaq srra is a clinical stage drug development company advancing next generation dna damage response ddr therapeutics for the treatment of patients with cancer soleno therapeutics nasdaq slno is developing a novel treatment for patients with praderwilli syndrome pws strongbridge biopharma focuses on rare diseases has resulted in a portfolio of innovative treatments for rare endocrine conditions surgical specialties is a medical device company that is marketing surgical products on a worldwide basis synapse biomedical is a medical device company developing neurostimulation products the company’s products have been approved by the fda for patients with spinal cord injury and amyotrophic lateral sclerosis trevena inc nasdaq trvn is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of gpcr targeted medicines tria beauty is a leader in lightbased therapeutic beauty systems that incorporate clinicallyproven aesthetic technologies for athome personal care regimens verona pharma lse aimvrpl is focused on developing new drugs for a range of respiratory diseases zai lab is a shanghaibased biopharmaceutical company our globallyexperienced drug development team is passionate about bringing transformative medicines to china and discovering and developing our own therapeutics for patients worldwide team  vivo capital lp access    select page team frank kung phd mba albert cha md phd edgar g engleman md shan fu ma chen yu md mba mahendra g shah phd hwachie lee lawrence wang md mba gaurav aggarwal md michael chang mba joseph siletto mba daisy xu ms dan dan dong phd qi zhu ma nina feng mba cfa andrew d goldberg md kevin dai pharmd bcop daniel qin nathan dau jd mba ethan zhao sue shao ms lingfei zhao ms waika cheng mba yixuan li ms jo shen phd yuhgeng tsay phd ronghuan lin ma emba frank kung managing partner albert cha managing partner edgar g engleman managing partner shan fu managing partner chen yu managing partner mahendra g shah managing director hwachie lee managing director  cio china lawrence wang managing director gaurav aggarwal managing director michael chang managing director joseph siletto managing director daisy xu general director dan dan dong principal qi zhu principal nina feng principal andrew d goldberg principal kevin dai principal daniel qin associate nathan dau associate ethan zhao associate sue shao associate lingfei zhao analyst waika cheng analyst yixuan li analyst jo shen venture partner yuhgeng tsay venture partner ronghuan lin advisor vivo capital and zq capital limited enter into an agreement to acquire angiotech pharmaceuticals vivo capital and zq capital limited enter into an agreement to acquire angiotech pharmaceuticals news provided by vivo capital dec    et share this article palo alto calif and vancouver british columbia dec   prnewswire  angiotech pharmaceuticals canada today announced that it has entered into a definitive agreement to be acquired by a group of investors led by vivo capital llc a leading healthcare focused investment firm and zq capital limited a leading chinabased investment and advisory firm  the investment syndicate also includes gso capital partners lp china orient asset management international holding limited and fung shing investments ltd  pursuant to the agreement the investment syndicate will acquire  of the shares of angiotech  in addition business development companies managed by affiliates of fs investments and subadvised by an affiliate of gso capital partners lp gso a division of the blackstone group provided senior secured financing into the transaction  the terms of the transaction were not disclosed  the closing of the transaction is expected to occur during the first quarter of  angiotech is a diversified medical device manufacturer of branded private label and oem products with more than  employees worldwide manufacturing facilities in england puerto rico mexico and germany and customers in over  countries worldwide  chen yu managing partner of vivo capital commented we are excited by the opportunity to work with the management team employees and customers of angiotech pharmaceuticals the company is well positioned for continued sales growth in their core markets of needles sutures and surgical knives we look forward to working with them to selectively expand the product offerings leveraging the multichannel strategy used by angiotech while driving strong geographic growth in key markets including china and other parts of asia simon shen chairman of zq capital commented we believe that angiotech fits perfectly with our growth strategy and are excited to welcome the company and its strong management team and employees to our portfolio  we are honored to have the opportunity to partner with the company to further enhance its comprehensive product offerings and markets and to expand its influence and benefits to millions of patients worldwide including in china the key shareholders in angiotech pharmaceuticals believe this is an excellent time to transition to new ownership and we are confident that the syndicate led by vivo capital and zq capital limited will continue the strong momentum already established commented jeff goldberg cochairman of the board of angiotech pharmaceuticals  the company has made significant progress under this shareholder group including enhancing the management team launching new products and line extensions while streamlining operations john barr ceo of angiotech commented i would first like to thank our customers for their continued support of angiotech we remain committed to continuing to improve our ability to service those customers our employees have worked hard and through significant change over the past few years we acknowledge their continued commitment to the mission of angiotech pharmaceuticals that centers on our customers i want to thank our shareholders and board for their investment long term support and strong guidance in angiotech and the critical role they played in our success the management team and i are excited to work with our new owners on a seamless transition and to further accelerate our growth while continuing to invest in improved quality and service for all our customers omelveny  myers llp is acting as legal advisor to the investment syndicate and paul hastings llp and magstone law acted as legal advisors to zq capital piper jaffray  co is acting as financial advisor and irell  manella llp as legal advisor respectively to angiotech about vivo capital vivo capital is a global healthcare focused investment firm formed in  with over  billion under management  vivo capital has offices in palo alto california beijing shanghai and taipei  vivos current portfolio includes more than  private and public biotechnology companies in the areas of biopharmaceuticals specialty pharmaceuticals and medical devices more information can be found at wwwvivocapitalcom about zq capital limited zq capital is an investment and advisory firm that specializes in identifying investing in and working together with global companies to realize their growth potential in the chinese market  utilizing its deep local knowledge of china as well as extensive relationships with financial institutions and leading entrepreneurs across numerous industries in asia zq capital is focused on partnering with successful global brands and leveraging its relationships in and knowledge of china to bring added value to its partners about china orient asset management international holding limited china orient asset management international holding limited is headquartered in hong kong and is a whollyowned subsidiary of china orient asset management group company  coami is the group companys primary overseas platform as of  december  coami has assets over hkd bn the key businesses of coami include investment corporate finance advisory nonperforming asset acquisitions and asset management about fung shing investment limited fung shing investment limited is an investment company that invests in various sectors including but not limited to media telecom healthcare real estate and financial institutions about angiotech angiotech pharmaceuticals has developed and manufactured branded private label and oem surgical instruments for over  years the company offers one of the most comprehensive portfolios of blades and sutures available including innovative products such as the quill knotless tissueclosure device headquartered in vancouver ca angiotech devotes itself to exceeding the needs of the specialty surgery market having trusted partnerships within dental ophthalmic plastic surgery dermatology orthopedics urology microsurgery veterinary and trauma specialties the key shareholders in angiotech include affiliates of blue mountain capital llc courage capital management llc and cetus capital llc   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesvivocapitalandzqcapitallimitedenterintoanagreementtoacquireangiotechpharmaceuticalshtml source vivo capital related links httpwwwvivoventurescom mar    et preview angiotech pharmaceuticals completes sale to investor syndicate led by vivo capital and zq capital jun    et preview vivo capital closes first healthcare venture capital focused fund at over  million my news release contains wide tables view fullscreen also from this source mar    et angiotech pharmaceuticals completes sale to investor syndicate explore more news releases in similar topics banking  financial services health care  hospitals medical equipment acquisitions mergers and takeovers you just read vivo capital and zq capital limited enter into an agreement to acquire angiotech pharmaceuticals news provided by vivo capital dec    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search vivo capital llc company profile  bloomberg feedback vivo capital llc private company company profile sector financials industry asset management subindustry investment companies vivo capital llc operates as an investment firm the company invests in healthcare therapeutics pharmaceutical and other sectors vivo capital serves clients worldwide corporate information address  hamilton avenue suite  palo alto ca  united states phone  fax  web url wwwvivocapitalcom board members managing dirventure partner company mahendra shah vivo capital llc from the web key executives frank f c kung managing partner albert cha managing partner edgar g engleman ed partnercofounder fu shan managing partner chenming yu managing partner mahendra g shah managing dirventure partner hwachie lee managing directorciochina gaurav aggarwal managing director cyber cao managing director lawrence wang managing director joseph siletto managing director tsay yuhgeng venture partner jo shen venture partner michael chang principal xu daisy principal dan dan dong principal qi zhu principal nina feng principal show more show less sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft vivo capital llc institutional portfolio  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  ownership  insider trades  institutional portfolio vivo capital llc  hamilton avenue suite  palo alto california    report date  position statistics total positions  new positions  increased positions  decreased positions  positions with activity  sold out positions  total mkt value in  millions  institutional holdings information is filed by major institutions on form f with the securities and exchange commission sector weighting energy basic materials industrials consumer cyclicals consumer noncyclicals financials healthcare  technology telecommunication services utilities total positions new increased decreased activity sold out  positions as of  company class value of shares s ▼ change in value s change  shares held aclaris therapeutics inc com     ascendis pharma a s sponsored adr  new  nabriva therapeutics plc shs  new  codexis inc com  new  advanced accelerator applic sponsored ads     strongbridge biopharma plc shs usd  new  aimmune therapeutics inc com  new  eiger biopharmaceuticals inc com  new  soleno therapeutics inc com     agile therapeutics inc com  new  trevena inc com  new  biopharmx corp com  new  foamix pharmaceuticals ltd shs  new  aurinia pharmaceuticals inc com   new  sierra oncology inc com  new  dynavax technologies corp com new  new  regenxbio inc com     crispr therapeutics ag namen akt  new  akari therapeutics plc sponsored adr  new  kalvista pharmaceuticals inc com  new   first previousnext last  latest news headlines sprint proposes merger with charter communications  wsj pm et   reuters union cheers as trucks kept out of us selfdriving legislation pm et   reuters rpthundreds of us counties at risk for no obamacare insurer in  pm et   reuters wells fargo faces angry questions after new sales abuses uncovered pm et   reuters us regulators weigh future of appeal in metlife case pm et   reuters view all latest headlines closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex